Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
1983-5-27
|
pubmed:abstractText |
A new intensive four drug combination chemotherapy regimen, termed PVeBV, consisting of cis-platinum, vinblastine, bleomycin, and VP-16, was administered to six previously untreated patients with poor prognosis advanced nonseminomatous testicular cancer and to four patients who had relapsed on primary platinum based regimens. The cis-platinum was administered in 250 ml of 3% saline at twice the dose (40 mg/m2 IV days 1-5 every three weeks) used in other treatment schedules. All six previously untreated patients achieved a complete remission. Four achieved a complete remission with three cycles of PVeBV while the other two patients achieved a complete remission with an additional cycle of cisplatinum and VP-16 at 200 mg/m2 IV X five followed by autologous bone marrow infusion. All four relapsed patients responded to PVeBV (two complete remissions and two partial remissions). There were no deaths associated with PVeBV therapy; however, myelosuppression was severe. There has been no renal toxicity (other than hypomagnesemia) observed with 35 cycles of high-dose platinum therapy in previously untreated patients. These results indicate that PVeBV is a promising chemotherapy regimen for the treatment of poor prognosis testicular cancer patients. Furthermore, it appears that cis-platinum can be administered at higher doses than previously used without an increase in renal toxicity if administered in hypertonic saline. The high-dose cis-platinum schedule, as used in PVeBV, warrants evaluation in other tumors which respond to standard-dose platinum therapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Bleomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0008-543X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
51
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1803-7
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:6187426-Antineoplastic Agents,
pubmed-meshheading:6187426-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:6187426-Bleomycin,
pubmed-meshheading:6187426-Bone Marrow Transplantation,
pubmed-meshheading:6187426-Cisplatin,
pubmed-meshheading:6187426-Etoposide,
pubmed-meshheading:6187426-Humans,
pubmed-meshheading:6187426-Male,
pubmed-meshheading:6187426-Prognosis,
pubmed-meshheading:6187426-Teratoma,
pubmed-meshheading:6187426-Testicular Neoplasms,
pubmed-meshheading:6187426-Vinblastine
|
pubmed:year |
1983
|
pubmed:articleTitle |
Treatment of poor prognosis nonseminomatous testicular cancer with a "high-dose" platinum combination chemotherapy regimen.
|
pubmed:publicationType |
Journal Article
|